Gufic BioSciences Ltd Q1 FY26 Earnings Analysis

- Indore facility peak revenue expected around Rs. 800 crore by FY 2028, reaching 70%-75% capacity utilization. - Revenue from Indore in FY 2026 projected between Rs. 100 to 150 crore, reaching EBITDA breakeven in FY 2026 and full profitability by FY 2027. - International business expected to grow from 16%-18% to about 25% of total revenue in next 2-3 years, potentially doubling exports in 3-5 years. - Contrast-media basket projected to contribute 5%-6% to the critical care segment within 2-3 years, expanding with new Gado-based product launches. - Critical care segment contributes over 50% of domestic revenue; infertility around 25%. - Botulinum toxin market penetration to reach 20%-26% in aesthetics and neurology within 3 years, aiming for Rs. 100 crore revenue. - Expected overall revenue growth rate of 15%-20% year-over-year in the next couple of years.

- Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27. - Peak revenue from Indore anticipated around Rs. 750-800 crores by FY '28 with 70%-75% capacity utilization. - Overall company revenue growth targeted at 15%-20% year-over-year for next 2 years. - International business expected to grow 1.5x to 2x in next 3 to 5 years, contributing ~25% of revenue. - EBITDA margin pressure due to Indore fixed costs, interest, and depreciation expected to ease by FY '26. - PAT margin was 8.53% for current financial year; improvement expected as Indore facility scales up. - Expanded product basket (e.g., contrast media, Botulinum toxin, IVIG) to support revenue and profitability growth. - Overall growth driven by domestic and international market expansions, product launches, and regulatory approvals.

- Indore facility is a key strategic capital investment, recently capitalized in Q3 FY '25. - Loan of Rs. 160 crore taken for Indore plant (Rs. 100 crore from Saraswat Bank and Rs. 60 crore from HDFC Bank). - Indore underwent extended media-fill and aseptic process validations to ensure export market compliance. - Indore plant poised to ramp up to ~30% capacity in FY '26 to achieve EBITDA breakeven; expected to be bottom-line accretive by FY '27. - Tech transfers initiated for 33 SKUs at Indore, with 15-18 completed, highlighting ongoing product development and capacity expansion. - Additional product launches planned, e.g., Gado-based contrast media and new biosimilars in fertility and neurocare divisions. - Company investing in product trials and clinical studies to support growth in critical care, fertility, and aesthetic segments. - Distribution expansion through international marketing (e.g., LATAM countries) indicates strategic market investment.

- The transcript does not explicitly mention any plans for new fundraising through debt or equity in the current or near future. - The company has already taken a Rs. 160 crore loan for the Indore plant (Rs. 100 crore from Saraswat Bank and Rs. 60 crore from HDFC Bank) with repayments started from April 1, 2024. - Debt repayments are ongoing and actively being serviced, with 12 months repayment equal to 16 months already completed. - There is no discussion or indication of raising additional capital via equity or further debt during the call. - The company appears focused on achieving EBITDA breakeven for the Indore facility by FY ’26 and managing existing financial obligations. Hence, no current or immediate new fundraising plans via debt or equity were disclosed in this call.

- The company has booked 16 major customer audits for its CMO business. - Five global regulatory inspections have been notified, with mock inspections underway. - Technology transfers for 33 SKUs from Navsari and 18 site transfers from other CMO partners are in progress. - Development of 15 new products at the Indore R&D center is in advanced stages. - The company has headroom to accept additional domestic orders currently. - However, excessive production is being avoided during the critical regulatory audit phase to maintain asset integrity.